| Impact of site of metastases in pancreatic ductal adenocarcinoma. A Arshad, S Zhao, L Wei, J Stephens, A Manne, AM Noonan, S Rahman Journal of Clinical Oncology 42 (3_suppl), 708-708, 2024 | | 2024 |
| A phase I clinical trial of riluzole in combination with mFOLFOX6 and bevacizumab in treating patients with metastatic colorectal cancer. C Li, AM Noonan, JL Hays, S Roychowdhury, PG Malalur, RT Elkhatib, ... Journal of Clinical Oncology 42 (3_suppl), 101-101, 2024 | | 2024 |
| Phase Ib adaptive study of dasatinib for the prevention of oxaliplatin-induced neuropathy in patients with gastrointestinal (GI) cancers receiving FOLFOX chemotherapy with or … AM Noonan, P Schnell, D Trunzo, W Thornton, PG Malalur, A Manne, ... Journal of Clinical Oncology 42 (3_suppl), 745-745, 2024 | | 2024 |
| Mucin 5 AC (MUC5AC) to predict pathologic treatment response (TR) to neoadjuvant chemotherapy (NAT) in resected-pancreatic ductal adenocarcinoma (R-PDA). A Manne, A Sheel, A Sara, AM Noonan, L Yu, W Yang, JL Hays, A Mittra, ... Journal of Clinical Oncology 42 (3_suppl), 690-690, 2024 | | 2024 |
| The impact of a pancreatic cancer multi-disciplinary clinic on patient-centric outcomes. C Hannon, PL Quinn, S Iacono, R Konik, A Sarna, G Di Tosto, ... Journal of Clinical Oncology 42 (3_suppl), 641-641, 2024 | | 2024 |
| Effect of Medicaid expansion in reducing racial disparities in early onset colorectal cancer S Rahman, R Patel, J Liu, A Gaba, R Maitra, A Acuna-Villaorduna, M Kim, ... Journal of Racial and Ethnic Health Disparities, 1-8, 2023 | 1 | 2023 |
| Neoadjuvant immunotherapy for localized pancreatic cancer: Challenges and early results RC Chick, AJ Gunderson, S Rahman, JM Cloyd Cancers 15 (15), 3967, 2023 | 6 | 2023 |
| A phase Ib adaptive study of dasatinib for the prevention of oxaliplatin-induced neuropathy in patients with gastrointestinal (GI) cancers receiving FOLFOX chemotherapy with or … AM Noonan, S Farid, P Schnell, D Trunzo, PG Malalur, N Jin, A Manne, ... Journal of Clinical Oncology 41 (16_suppl), e15613-e15613, 2023 | | 2023 |
| Real-world experience and outcomes of immune-checkpoint inhibitors (ICI) in hepatocellular carcinoma (HCC). S Paul, E Min, KK Benson, M Xu, AM Noonan, A Mittra, PG Malalur, ... Journal of Clinical Oncology 41 (16_suppl), e16155-e16155, 2023 | | 2023 |
| Predictors of response in advanced colorectal cancer (CRC) patients treated with immune-checkpoint inhibitors (ICI). KK Benson, S Paul, E Min, M Xu, AM Noonan, A Mittra, PG Malalur, ... Journal of Clinical Oncology 41 (16_suppl), e15579-e15579, 2023 | | 2023 |
| Risk factors (RF) for poor outcomes in esophageal (EC) and gastric (GC) adenocarcinomas treated with immune-checkpoint inhibitors (ICI). E Min, KK Benson, S Paul, M Xu, AM Noonan, A Mittra, PG Malalur, ... Journal of Clinical Oncology 41 (16_suppl), e16032-e16032, 2023 | | 2023 |
| Outcome of stem cell transplantation in HTLV-1-associated north American adult T-cell leukemia/lymphoma AH Bazarbachi, D Reef, H Narvel, R Patel, R Al Hamed, S Vikash, ... Clinical Hematology International 5 (2), 78-91, 2023 | 3 | 2023 |
| 676 Urgent care referrals demonstrate need for “real-time” dermatology e-consultation S Rahman, A Bowden, C Green, JR Wolf Journal of Investigative Dermatology 143 (5), S116, 2023 | | 2023 |
| 677 Need for improved access to dermatologic care in underserved populations A Bowden, S Rahman, C Green, JR Wolf Journal of Investigative Dermatology 143 (5), S116, 2023 | | 2023 |
| Safety of Direct Acting Oral Anticoagulants (DOACs) in Comparison to Enoxaparin in Gastrointestinal and Genito-Urinary Cancers MKHHB Shafia Rahman1, Juan Trias2*, Mohammad Barouqa3* Journal of Basic and Clinical Pharmacy, 2023 | | 2023 |
| Understanding the clinical significance of MUC5AC in biliary tract Cancers KK Benson, A Sheel, S Rahman, A Esnakula, A Manne Cancers 15 (2), 433, 2023 | 1 | 2023 |
| Allogeneic but Not Autologous Stem Cell Transplantation Improves Outcome in HTLV-1-Associated North American Adult T-Cell Leukemia/Lymphoma AH Bazarbachi, DK Reef, H Narvel, R Patel, R Al Hamed, A Thakkar, ... Blood 140 (Supplement 1), 662-664, 2022 | | 2022 |
| Outcomes of Autologous Stem Cell Transplantation for Relapsed DLBCL in Single Center Serving a Minority Population T Jain, AH Bazarbachi, E Rabinovich, A Abbasi, K Pradhan, DK Reef, ... Blood 140 (Supplement 1), 13225-13227, 2022 | | 2022 |
| Older Age and Neutrophil-to-Lymphocyte Ratio (NLR) Are Predictors of Illness Severity and COVID-Related Mortality in a Multiethnic Urban Cohort of Hematologic Neoplasms … A D'Aiello, S Zareef, E Atalla, A Abbasi, K Pradhan, A Lombardo, F Khatun, ... Blood 140 (Supplement 1), 10949-10950, 2022 | | 2022 |
| High seroconversion rates amongst black and Hispanics with hematologic malignancies after SARS-CoV-2 vaccination LC Shapiro, A Thakkar, R Gali, JD Gonzalez-Lugo, AH Bazarbachi, ... Leukemia & Lymphoma 63 (10), 2484-2488, 2022 | 6 | 2022 |
